Hongri Pharmaceutical: Injectable Polymyxin E Methanesulfonate Sodium Obtains Approval for a Clinical Trial Application

Hongri Pharmaceutical announced that the company recently received the drug clinical trial approval notice issued by the National Medical Products Administration (Notification No.: 2026LP00701). According to the Drug Administration Law of the People’s Republic of China and relevant regulations, after review by the National Medical Products Administration, the company’s application for injectable polymyxin E sulfate sodium meets the relevant requirements for drug registration, and approval is granted to conduct clinical trials of this product.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin